Get the Stockscreener App
7.71
9.93%
-0.85
After Hours:
7.75
0.04
+0.52%
Quantum Biopharma Ltd stock is traded at $7.71, with a volume of 939.29K.
It is down -9.93% in the last 24 hours and up +69.45% over the past month.
See More
Previous Close:
$8.56
Open:
$8.79
24h Volume:
939.29K
Relative Volume:
0.36
Market Cap:
$16.08M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+38.92%
1M Performance:
+69.45%
6M Performance:
+92.75%
1Y Performance:
+0.00%
1-Day Range:
$6.4519
$8.98
1-Week Range:
$5.38
$12.45
52-Week Range:
$2.70
$18.00
Quantum Biopharma Ltd Stock (QNTM) Company Profile
Compare QNTM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QNTM
Quantum Biopharma Ltd
|
7.71 | 16.08M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
164.65 | 73.07B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.87 | 47.43B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.29 | 45.72B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.37 | 17.71B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
308.27 | 14.37B | 2.76B | 1.11B | 898.10M | 22.77 |
Quantum Biopharma Ltd Stock (QNTM) Latest News
Quantum BioPharma completes $5 million funding round - Investing.com India
Quantum BioPharma Secures Final Tranche of $5 Million Financing - TipRanks
Quantum Biopharma Announces Closing of Final $2.42 Million - GlobeNewswire
Quantum BioPharma Closes $5M Deal While Unveiling Revolutionary Emergency Alcohol Treatment - Stock Titan
Quantum BioPharma Invests $65K in Enhanced Investor Communications Strategy - Stock Titan
Promising Biotech Stocks To Watch Now – March 28th - Defense World
Quantum BioPharma reports progress in drug trials By Investing.com - Investing.com South Africa
Quantum BioPharma pushes clinical pipeline after rebranding - Green Market Report
Quantum BioPharma reports progress in drug trials - Investing.com
Quantum BioPharma stock soars on removal of uncertainty related to going concern - Investing.com
Quantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern - Bluefield Daily Telegraph
Quantum Biopharma Achieves Financial Milestone: Going Concern Warning Lifted as Clinical Trials Show Promise - Stock Titan
Quantum BioPharma Reports Strong 2024 Financials and Advances in Clinical Trials - TipRanks
Quantum Biopharma’s 2024 Financial Statements Show Strong Improvements in Cash, Working - Bluefield Daily Telegraph
Quantum Biopharma’s 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern - GlobeNewswire
Quantum Biopharma Achieves Major Turnaround: Going Concern Lifted as Cash Position Strengthens - Stock Titan
BiomednewsbreaksQuantum Biopharma Ltd. (NASDAQ: QNTM) Reports Q4 And Full-Year 2024 Financial Results, Highlights Breakthroughs In Alcohol Detox And MS Treatments - MENAFN.COM
Quantum BioPharma adds Terry Lynch to its board By Investing.com - Investing.com South Africa
Quantum BioPharma adds Terry Lynch to its board - Investing.com India
Quantum BioPharma Strengthens Board with Terry Lynch Appointment - TipRanks
Quantum Biopharma Announces Leading Crusader Against Naked - GlobeNewswire
Market Integrity Champion Terry Lynch Strengthens Quantum BioPharma Leadership - Stock Titan
Quantum BioPharma's Licensee Introduces New Alcohol Detox Packs in the US - MarketScreener
Quantum BioPharma (QNTM) Stock Rallies Following Key Business Development - Stocks Telegraph
Quantum BioPharma Licensee Celly Nutrition Expands unbuzzd™ Alcohol Detox Product Lineup for Retail Sales - Quantisnow
Global Weather Concerns Support Coffee Prices - The Globe and Mail
Quantum BioPharma Ltd expected to post a loss of 80 cents a shareEarnings Preview - TradingView
Every Plug Power Investor Should Keep an Eye on This Number - The Globe and Mail
Sandpiper Asset Management selling at Extendicare (EXE) - The Globe and Mail
Quantum BioPharma Ltd - Stockhouse Publishing
Quantum BioPharma Boosts Crypto Holdings to $3.5M, Eyes Digital Transactions - TradingPedia
Quantum BioPharma Ltd. Expands Cryptocurrency Holdings by $1.5 Million, Totaling $3.5 Million in Bitcoin and Alternatives - Nasdaq
Quantum BioPharma Continues to Grow Its Crypto Assets and Diversify Its Treasury With the Purchase of Another USD $1,500,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies - The Manila Times
Quantum BioPharma Continues to Grow Its Crypto Assets and - GlobeNewswire
Quantum Biopharma Continues To Grow Its Crypto Assets And Diversify Its Treasury With The Purchase Of Another USD $1,500,000 Worth Of Bitcoin (BTC) And Other Cryptocurrencies - MENAFN.COM
Quantum BioPharma Doubles Down on Crypto Strategy: Adds $1.5M in Bitcoin to Treasury - StockTitan
Denison Announces Appointment of Former OPG CEO Ken Hartwick to its Board of Directors - The Globe and Mail
Cannabis Stocks To Follow Today – March 18th - Defense World
3 Hot Stock Upgrades as Analysts Look Ahead to Q2 Earnings - The Globe and Mail
Quantum BioPharma Unaware of Any Material Change - Newsfile
The Smartest Vanguard ETF to Buy With $1,000 Right Now - The Globe and Mail
Tariffs and Supply Issues Hit Mission Produce (AVO) Share Price Despite Earnings Beat - The Globe and Mail
Quantum BioPharma Provides Corporate Update - Yahoo Finance
3 Market-Beating Stocks to Target This Week - The Globe and Mail
Massive News for Intel Stock Investors - The Globe and Mail
Quantum BioPharma Ltd (NASDAQ: QNTM): A Bold Step into the Future of Biopharmaceutical Innovation - openPR
Quantum BioPharma Completes Phase 1 Trial Of Lucid-21-302 For Multiple Sclerosis Treatment - Nasdaq
Quantum Biopharma up in U.S. Pre-market, Says Phase 1 Lucid-MS Trial Completed With no Safety Concerns - Marketscreener.com
Quantum BioPharma Reports No Safety Concerns for Lucid-MS Following Successful Phase 1 Trial - Nasdaq
Quantum Biopharma Announces Completion of the Phase 1 - GlobeNewswire
Quantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302 - Niagara Falls Review
Quantum Biopharma Ltd Stock (QNTM) Financials Data
There is no financial data for Quantum Biopharma Ltd (QNTM). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.57%
1.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):